Journal
MOLECULES
Volume 24, Issue 15, Pages -Publisher
MDPI
DOI: 10.3390/molecules24152739
Keywords
iridium(III) complex; apoptosis; mitochondria; cancer
Funding
- Hong Kong Baptist University [FRG2/17-18/003]
- Health and Medical Research Fund [HMRF/14150561]
- National Natural Science Foundation of China [21575121, 21775131, 21762018]
- Hong Kong Baptist University Century Club Sponsorship Scheme 2018
- Interdisciplinary Research Matching Scheme [RC-IRMS/16-17/03]
- Interdisciplinary Research Clusters Matching Scheme [RC-IRCs/17-18/03]
- Collaborative Research Fund [C5026-16G]
- SKLEBA
- HKBU Strategic Development Fund [SKLP_1718_P04]
- Science and Technology Development Fund, Macau SAR [0072/2018/A2]
- University of Macau [MYRG2016-00151-ICMS-QRCM, MYRG2018-00187-ICMS]
Ask authors/readers for more resources
Targeting apoptosis is a principal strategy in the design of anticancer drugs. In recent years, non-platinum-based scaffolds have been exploited as viable candidates for the exploitation of anticancer agents with potentially lower toxicity than the widely used cisplatin analogues. This review highlights the latest advances in developing iridium(III) complexes as anticancer agents that act particularly via targeting apoptotic cell death in cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
